Interplay between ATRX and IDH1 mutations governs innate immune responses in diffuse gliomas.
Journal
Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555
Informations de publication
Date de publication:
25 Jan 2024
25 Jan 2024
Historique:
received:
24
04
2023
accepted:
10
01
2024
medline:
26
1
2024
pubmed:
26
1
2024
entrez:
25
1
2024
Statut:
epublish
Résumé
Stimulating the innate immune system has been explored as a therapeutic option for the treatment of gliomas. Inactivating mutations in ATRX, defining molecular alterations in IDH-mutant astrocytomas, have been implicated in dysfunctional immune signaling. However, little is known about the interplay between ATRX loss and IDH mutation on innate immunity. To explore this, we generated ATRX-deficient glioma models in the presence and absence of the IDH1
Identifiants
pubmed: 38272925
doi: 10.1038/s41467-024-44932-w
pii: 10.1038/s41467-024-44932-w
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
730Subventions
Organisme : NCI NIH HHS
ID : R01 CA255788
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA255788
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA255788
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA240338
Pays : United States
Informations de copyright
© 2024. The Author(s).
Références
Ostrom, Q. T., Cioffi, G., Waite, K., Kruchko, C. & Barnholtz-Sloan, J. S. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2014–2018. Neuro. Oncol. 23, iii1–iii105 (2021).
pubmed: 34608945
pmcid: 8491279
doi: 10.1093/neuonc/noab200
Cancer Genome Atlas Research, N. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455, 1061–1068 (2008).
doi: 10.1038/nature07385
Louis, D. N. et al. The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro. Oncol. 23, 1231–1251 (2021).
pubmed: 34185076
pmcid: 8328013
doi: 10.1093/neuonc/noab106
Whitfield, B. T. & Huse, J. T. Classification of adult-type diffuse gliomas: impact of the World Health Organization 2021 update. Brain Pathol. 32, e13062 (2022).
pubmed: 35289001
pmcid: 9245936
doi: 10.1111/bpa.13062
Weller, M. et al. EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood. Nat. Rev. Clin. Oncol. 18, 170–186 (2021).
pubmed: 33293629
doi: 10.1038/s41571-020-00447-z
Mohile, N. A. et al. Therapy for diffuse astrocytic and oligodendroglial tumors in adults: ASCO-SNO guideline. J. Clin. Oncol. 40, 403–426 (2022).
pubmed: 34898238
doi: 10.1200/JCO.21.02036
Waldman, A. D., Fritz, J. M. & Lenardo, M. J. A guide to cancer immunotherapy: from T cell basic science to clinical practice. Nat. Rev. Immunol. 20, 651–668 (2020).
pubmed: 32433532
pmcid: 7238960
doi: 10.1038/s41577-020-0306-5
Hodi, F. S. et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363, 711–723 (2010).
pubmed: 20525992
pmcid: 3549297
doi: 10.1056/NEJMoa1003466
Reardon, D. A. et al. Effect of Nivolumab vs Bevacizumab in patients with recurrent glioblastoma: the CheckMate 143 phase 3 randomized clinical trial. JAMA Oncol. 6, 1003–1010 (2020).
pubmed: 32437507
doi: 10.1001/jamaoncol.2020.1024
Lang, F. F. et al. Phase I study of DNX-2401 (Delta-24-RGD) oncolytic adenovirus: replication and immunotherapeutic effects in recurrent malignant glioma. J. Clin. Oncol. 36, 1419–1427 (2018).
pubmed: 29432077
pmcid: 6075856
doi: 10.1200/JCO.2017.75.8219
Desjardins, A. et al. Recurrent glioblastoma treated with recombinant poliovirus. N. Engl. J. Med. 379, 150–161 (2018).
pubmed: 29943666
pmcid: 6065102
doi: 10.1056/NEJMoa1716435
Fudaba, H. & Wakimoto, H. Oncolytic virus therapy for malignant gliomas: entering the new era. Expert Opin. Biol. Ther. 23, 269–282 (2023).
pubmed: 36809883
doi: 10.1080/14712598.2023.2184256
Brown, M. C. et al. Viral infection of cells within the tumor microenvironment mediates antitumor immunotherapy via selective TBK1-IRF3 signaling. Nat. Commun. 12, 1–16 (2021).
doi: 10.1038/s41467-021-22088-1
Kaufman, H. L., Kohlhapp, F. J. & Zloza, A. Oncolytic viruses: a new class of immunotherapy drugs. Nat. Rev. Drug Discov. 14, 642–662 (2015).
pubmed: 26323545
pmcid: 7097180
doi: 10.1038/nrd4663
Fitzgerald, K. A. et al. IKKepsilon and TBK1 are essential components of the IRF3 signaling pathway. Nat. Immunol. 4, 491–496 (2003).
pubmed: 12692549
doi: 10.1038/ni921
Kato, H. et al. Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses. Nature 441, 101–105 (2006).
pubmed: 16625202
doi: 10.1038/nature04734
Alexopoulou, L., Holt, A. C., Medzhitov, R. & Flavell, R. A. Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature 413, 732–738 (2001).
pubmed: 11607032
doi: 10.1038/35099560
Ishikawa, H., Ma, Z. & Barber, G. N. STING regulates intracellular DNA-mediated, type I interferon-dependent innate immunity. Nature 461, 788–792 (2009).
pubmed: 19776740
pmcid: 4664154
doi: 10.1038/nature08476
Cancer Genome Atlas Research, N. et al. Comprehensive, integrative genomic analysis of diffuse lower-grade gliomas. N. Engl. J. Med. 372, 2481–2498 (2015).
doi: 10.1056/NEJMoa1402121
Haase, S. et al. Mutant ATRX: uncovering a new therapeutic target for glioma. Expert Opin. Ther. Targets 22, 599–613 (2018).
pubmed: 29889582
pmcid: 6044414
doi: 10.1080/14728222.2018.1487953
Pan, D. et al. A major chromatin regulator determines resistance of tumor cells to T cell-mediated killing. Science 359, 770–775 (2018).
pubmed: 29301958
pmcid: 5953516
doi: 10.1126/science.aao1710
Griffin, G. K. et al. Epigenetic silencing by SETDB1 suppresses tumour intrinsic immunogenicity. Nature 595, 309–314 (2021).
pubmed: 33953401
pmcid: 9166167
doi: 10.1038/s41586-021-03520-4
Babikir, H. et al. ATRX regulates glial identity and the tumor microenvironment in IDH-mutant glioma. Genome Biol. 22, 311 (2021).
pubmed: 34763709
pmcid: 8588616
doi: 10.1186/s13059-021-02535-4
Hu, C. et al. ATRX loss promotes immunosuppressive mechanisms in IDH1 mutant glioma. Neuro. Oncol. 24, 888–900 (2022).
pubmed: 34951647
doi: 10.1093/neuonc/noab292
Amankulor, N. M. et al. Mutant IDH1 regulates the tumor-associated immune system in gliomas. Genes Dev. 31, 774–786 (2017).
pubmed: 28465358
pmcid: 5435890
doi: 10.1101/gad.294991.116
Venteicher, A. S. et al. Decoupling genetics, lineages, and microenvironment in IDH-mutant gliomas by single-cell RNA-seq. Science (New York, N.Y.) 355, eaai8478 (2017).
pubmed: 28360267
doi: 10.1126/science.aai8478
Tirosh, I. et al. Single-cell RNA-seq supports a developmental hierarchy in human oligodendroglioma. Nature 539, 309–313 (2016).
pubmed: 27806376
pmcid: 5465819
doi: 10.1038/nature20123
Hambardzumyan, D., Amankulor, N. M., Helmy, K. Y., Becher, O. J. & Holland, E. C. Modeling adult gliomas using RCAS/t-va technology. Transl. Oncol. 2, 89–95 (2009).
pubmed: 19412424
pmcid: 2670576
doi: 10.1593/tlo.09100
Dyer, M. A., Qadeer, Z. A., Valle-Garcia, D. & Bernstein, E. ATRX and DAXX: mechanisms and mutations. Cold Spring Harb. Perspect Med. 7, a026567 (2017).
pubmed: 28062559
pmcid: 5334245
doi: 10.1101/cshperspect.a026567
Kirby, A. J. & Finnerty, G. T. New strategies for managing adult gliomas. J. Neurol. 268, 3666–3674 (2021).
pubmed: 32542524
doi: 10.1007/s00415-020-09884-3
Mukherjee, J. et al. Mutant IDH1 cooperates with ATRX loss to drive the alternative lengthening of telomere phenotype in glioma. Cancer Res. 78, 2966–2977 (2018).
pubmed: 29545335
pmcid: 10578296
doi: 10.1158/0008-5472.CAN-17-2269
Kohanbash, G. et al. Isocitrate dehydrogenase mutations suppress STAT1 and CD8+ T cell accumulation in gliomas. J. Clin. Invest. 127, 1425–1437 (2017).
pubmed: 28319047
pmcid: 5373859
doi: 10.1172/JCI90644
Pirozzi, C. J. & Yan, H. The implications of IDH mutations for cancer development and therapy. Nat. Rev. Clin. Oncol. 18, 645–661 (2021).
pubmed: 34131315
doi: 10.1038/s41571-021-00521-0
Waitkus, M. S., Diplas, B. H. & Yan, H. Biological role and therapeutic potential of IDH mutations in cancer. Cancer Cell 34, 186–195 (2018).
pubmed: 29805076
pmcid: 6092238
doi: 10.1016/j.ccell.2018.04.011
Golub, D. et al. Mutant isocitrate dehydrogenase inhibitors as targeted cancer therapeutics. Front Oncol. 9, 417 (2019).
pubmed: 31165048
pmcid: 6534082
doi: 10.3389/fonc.2019.00417
Pusch, S. et al. Pan-mutant IDH1 inhibitor BAY 1436032 for effective treatment of IDH1 mutant astrocytoma in vivo. Acta Neuropathol. 133, 629–644 (2017).
pubmed: 28124097
doi: 10.1007/s00401-017-1677-y
Wick, A. et al. Phase I assessment of safety and therapeutic activity of BAY1436032 in patients with IDH1-mutant solid tumors. Clin. Cancer Res. 27, 2723–2733 (2021).
pubmed: 33622704
doi: 10.1158/1078-0432.CCR-20-4256
Lee, A. H. et al. Neoadjuvant PD-1 blockade induces T cell and cDC1 activation but fails to overcome the immunosuppressive tumor associated macrophages in recurrent glioblastoma. Nat. Commun. 12, 6938 (2021).
pubmed: 34836966
pmcid: 8626557
doi: 10.1038/s41467-021-26940-2
Zhang, X. et al. IDH mutant gliomas escape natural killer cell immune surveillance by downregulation of NKG2D ligand expression. Neuro. Oncol. 18, 1402–1412 (2016).
pubmed: 27116977
pmcid: 5035522
doi: 10.1093/neuonc/now061
Chen, Y.-A. et al. Extrachromosomal telomere repeat DNA is linked to ALT development via cGAS-STING DNA sensing pathway. Nat. Struct. Mol. Biol. 24, 1124–1131 (2017).
pubmed: 29106411
doi: 10.1038/nsmb.3498
Wan, D., Jiang, W. & Hao, J. Research advances in how the cGAS-STING pathway controls the cellular inflammatory response. Front Immunol. 11, 615 (2020).
pubmed: 32411126
pmcid: 7198750
doi: 10.3389/fimmu.2020.00615
Floyd, W. et al. Atrx deletion impairs CGAS/STING signaling and increases sarcoma response to radiation and oncolytic herpesvirus. J. Clin. Invest. 133, e149310 (2023).
pubmed: 37200088
pmcid: 10313374
doi: 10.1172/JCI149310
Zheng, J. et al. RIG-I-like receptors: molecular mechanism of activation and signaling. Adv. Immunol. 158, 1–74 (2023).
pubmed: 37453753
doi: 10.1016/bs.ai.2023.03.001
Sadic, D. et al. Atrx promotes heterochromatin formation at retrotransposons. EMBO Rep. 16, 836–850 (2015).
pubmed: 26012739
pmcid: 4515123
doi: 10.15252/embr.201439937
Valenzuela, M., Amato, R., Sgura, A., Antoccia, A. & Berardinelli, F. The multiple facets of ATRX protein. Cancers (Basel) 13, 2211 (2021).
pubmed: 34062956
doi: 10.3390/cancers13092211
Chiappinelli, K. B. et al. Inhibiting DNA methylation causes an interferon response in cancer via dsrna including endogenous retroviruses. Cell 162, 974–986 (2015).
pubmed: 26317466
pmcid: 4556003
doi: 10.1016/j.cell.2015.07.011
Canadas, I. et al. Tumor innate immunity primed by specific interferon-stimulated endogenous retroviruses. Nat. Med. 24, 1143–1150 (2018).
pubmed: 30038220
pmcid: 6082722
doi: 10.1038/s41591-018-0116-5
Roulois, D. et al. DNA-demethylating agents target colorectal cancer cells by inducing viral mimicry by endogenous transcripts. Cell 162, 961–973 (2015).
pubmed: 26317465
pmcid: 4843502
doi: 10.1016/j.cell.2015.07.056
Johnson, B. E. et al. Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma. Science 343, 189–193 (2014).
pubmed: 24336570
doi: 10.1126/science.1239947
Ohba, S. et al. Mutant IDH1 expression drives TERT promoter reactivation as part of the cellular transformation process. Cancer Res. 76, 6680–6689 (2016).
pubmed: 27758882
pmcid: 5290072
doi: 10.1158/0008-5472.CAN-16-0696
Szatmari, T. et al. Detailed characterization of the mouse glioma 261 tumor model for experimental glioblastoma therapy. Cancer Sci. 97, 546–553 (2006).
pubmed: 16734735
doi: 10.1111/j.1349-7006.2006.00208.x
Wang, Y. et al. G-quadruplex DNA drives genomic instability and represents a targetable molecular abnormality in ATRX-deficient malignant glioma. Nat. Commun. 10, 1–14 (2019).
Struys, E. A., Jansen, E. E., Verhoeven, N. M. & Jakobs, C. Measurement of urinary D- and L-2-hydroxyglutarate enantiomers by stable-isotope-dilution liquid chromatography-tandem mass spectrometry after derivatization with diacetyl-L-tartaric anhydride. Clin. Chem. 50, 1391–1395 (2004).
pubmed: 15166110
doi: 10.1373/clinchem.2004.033399
Pirozzi, C. J. et al. Mutant IDH1 disrupts the mouse subventricular zone and alters brain tumor progression. Mol. Cancer Res. 15, 507–520 (2017).
pubmed: 28148827
pmcid: 5415422
doi: 10.1158/1541-7786.MCR-16-0485
Waitkus, M. S. et al. Adaptive evolution of the GDH2 allosteric domain promotes gliomagenesis by resolving IDH1(R132H)-induced metabolic liabilities. Cancer Res. 78, 36–50 (2018).
pubmed: 29097607
doi: 10.1158/0008-5472.CAN-17-1352